Retatrutide 2026: The Emerging Triple-Agonist Market

About this review

AJ Pakpour's independent evidence review examines retatrutide's clinical development and the American consumer market that emerged around it before regulatory approval. The paper brings together clinical research, trial registrations, sponsor disclosures and regulatory documents, distinguishing published evidence from preliminary announcements.

What the paper covers

• →Retatrutide's GIP, GLP-1 and glucagon receptor activity
• →Phase 2 and Phase 3 clinical evidence
• →Safety findings and unanswered questions
• →Comparisons with semaglutide and tirzepatide
• →Regulatory developments and the American gray market
• →The limitations of certificates of analysis as evidence of injectable safety

Retatrutide (LY3437943) is an investigational triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GcgR) under development by Eli Lilly and Company. This review synthesizes the available clinical evidence as of September 30, 2026, drawing on peer-reviewed publications, sponsor-reported topline results, trial registrations, and publicly available regulatory documents.

Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated dose-dependent weight reduction of up to 24.2% at 48 weeks in adults with obesity. Topline results from the Phase 3 TRIUMPH-1 trial, announced by Eli Lilly in May 2026, reported mean body weight reduction of 28.3% at 80 weeks in the 12 mg arm. These sponsor-reported results have not yet been published in a peer-reviewed journal and have not been independently verified. The distinction between published peer-reviewed findings and sponsor-reported preliminary results is maintained throughout this review.

The review documents the emergence of a gray market for retatrutide in the United States, characterized by the sale of research-grade peptides, compounded formulations of uncertain provenance, and direct-to-consumer telehealth prescribing outside established clinical protocols. It examines the regulatory framework governing these activities, including FDA enforcement actions, the status of compounding under 503A and 503B pathways, and the limitations of certificates of analysis as proxies for injectable safety.

Safety data from Phase 2 trials identified gastrointestinal adverse events as the most common treatment-emergent effects, with nausea, vomiting, and diarrhea occurring in a dose-dependent pattern. Class-level precautions applicable to GLP-1 receptor agonists are reviewed. Long-term safety data beyond 80 weeks are not available. Retatrutide is not approved by the FDA or any regulatory authority as of the research cutoff date.

This review is an independent evidence synthesis. It does not constitute clinical guidance, medical advice, or legal counsel. Repository publication does not establish peer review. See Appendix E for the author's full disclosures.